Hubbry Logo
Phakic intraocular lensPhakic intraocular lensMain
Open search
Phakic intraocular lens
Community hub
Phakic intraocular lens
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Phakic intraocular lens
Phakic intraocular lens
Phakic intraocular lens
View on Wikipedia
from Wikipedia
Phakic intraocular lens
Photo of an eye after PIOL-implantation, 24 hours after surgery. The lens is visible in front of the iris; the pupil is still small due to presurgery eyedrops.

A phakic intraocular lens (PIOL) is an intraocular lens that is implanted surgically into the eye to correct refractive errors without removing the natural lens (also known as "phakos", hence the term). Intraocular lenses that are implanted into eyes after the eye's natural lens has been removed during cataract surgery are known as pseudophakic.

Phakic intraocular lenses are indicated for patients with high refractive errors when the usual laser options for surgical correction (LASIK and PRK) are contraindicated.[1][2] Phakic IOLs are designed to correct high myopia ranging from −5 to −20 D if the patient has enough anterior chamber depth (ACD) of at least 3 mm.[3]

Three types of phakic IOLs are available:

Medical uses

[edit]
An installed PIOL, with flash photography
An installed PIOL, without flash photography

LASIK can correct myopia up to -12 to -14 D. The higher the intended correction the thinner and flatter the cornea will be post-operatively. For LASIK surgery, one has to preserve a safe residual stromal bed of at least 250 μm, preferably 300 μm. Beyond these limits there is an increased risk of developing corneal ectasia (i.e. corneal forward bulging) due to thin residual stromal bed which results in loss of visual quality. Due to the risk of higher order aberrations there is a current trend toward reducing the upper limits of LASIK and PRK to around -8 to -10 D.[4] Phakic intraocular lenses are safer than excimer laser surgery for those with significant myopia.[5]

Phakic intraocular lenses are contraindicated in patients who do not have a stable refraction for at least 6 months or are 21 years of age or younger. Preexisting eye disorders such as uveitis are another contraindication.

Although PIOLs for hyperopia are being investigated, there is less enthusiasm for these lenses because the anterior chamber tends to be shallower than in myopic patients. A hyperopic model ICL (posterior chamber PIOL) is available.

A corneal endothelium cell count of less than 2000 to 2500 cells per mm2 is a relative contraindication for PIOL implantation.[2]

Advantages

[edit]

PIOLs have the advantage of treating a much larger range of myopic and hyperopic refractive errors than can be safely and effectively treated with corneal refractive surgery. The skills required for insertion are, with a few exceptions, similar to those used in cataract surgery. The equipment is significantly less expensive than an excimer laser and is similar to that used for cataract surgery. In addition, the PIOL is removable; therefore, the refractive effect should theoretically be reversible. However, any intervening damage caused by the PIOL would most likely be permanent. When compared with clear lens extraction, or refractive lens exchange the PIOL has the advantage of preserving natural accommodation and may have a lower risk of postoperative retinal detachment because of the preservation of the crystalline lens and minimal vitreous destabilization.[1]

Disadvantages

[edit]

PIOL insertion is an intraocular procedure. With all surgeries there are associated risks. In addition, each PIOL style has its own set of associated risks. In the case of PIOLs made of polymethylmethacrylate (PMMA), surgical insertion requires a larger incision, which may result in postoperative astigmatism. By comparison, PIOLS made of a foldable gel-like substance require a very small incision due to the flexibility of the material and thus significantly reduces astigmatism risk. In the cases where refractive outcomes are not optimal, LASIK can be used for fine-tuning. If a patient eventually develops a visually significant cataract, the PIOL will have to be explanted at the time of cataract surgery, possibly through a larger-than-usual incision.[citation needed]

Another concern is progressive shallowing of the anterior chamber which normally occurs with advancing age due to the growth of the eye's natural lens. Multiple studies have shown a 12–17 μm/year decrease in the anterior chamber depth with aging.[6][7] If a phakic IOL patient is assumed to have a 50-year lifespan, the overall decline in ACD may add up to 0.6–0.85 millimetres (0.024–0.033 in); long-term data about this effect are not available. This concern is more important in implantable collamer lens because it is implanted in the narrowest part of the anterior segment.[citation needed][clarification needed]

Contraindications

[edit]
See also: Cataract surgery § Contraindications

Lower levels of acceptable risk may be appropriate for implantation of phakic lenses than for cataract surgery, as the risk-benefit trade-off is less for improving vision than for restoring vision.[citation needed]

Complications

[edit]
  • Glare and halos which may cause night time symptoms especially in patients with larger pupil diameters.
  • Cataract which is the most crucial concern for the Sulcus-Supported PIOLs. According to FDA approximately 6% to 7% of eyes develop anterior subcapsular opacities at 7+ years following Implantable Collamer Lens implantation and 1% to 2% progress to clinically significant cataract during the same period, especially very high myopes and older patients.[4][8]
  • Endothelial cell loss especially for the anterior chamber PIOLs. A study observed a continual steady loss of endothelial cells of -1.8% per year.[4]
  • Pigment dispersion may be seen in iris-fixated and sulcus-supported PIOLs due to iris abrasion during pupillary movement.
  • Other complications include glaucoma and PIOL dislocation or decentration.

Preoperative evaluation

[edit]

Anterior chamber depth (ACD, i.e. the distance between the crystalline lens and cornea including the corneal thickness) is required before the surgery and measured with the use of ultrasound.

Iris-fixated IOLs are fixated to iris therefore they have the advantage of being one size (8.5 mm).

Sulcus-supported IOLs need to be implanted in the ciliary sulcus which may have various diameters among individuals, therefore anterior chamber diameter needs to be measured with a calliper or with the use of eye imaging instruments such as Orbscan and high frequency ultrasound. A calliper and Orbscan measure the external limbus-to-limbus diameter of anterior chamber (white-to-white diameter) which provides an approximate estimation of AC diameter but UBM and OCT offer a more adequate measurement of the sulcus diameter (sulcus-to-sulcus diameter) and should be used when available.[4]

Power calculation

[edit]

The power of phakic lens is independent of the axial length of the eye. Rather it depends on central corneal power, anterior chamber depth (ACD) and patient refraction (preoperative spherical equivalent). The most common formula for calculating the power of phakic IOL is the following:[2]

P : Power of phakic IOL
n : Refractive Index of Aqueous (1.336)
K : Central corneal power in diopters
R : Patient Refraction at the corneal vertex
d : Effective lens position in mm

The effective lens position is calculated as the difference between the anterior chamber depth and the distance between the PIOL and the crystalline lens. From ultrasonographic examinations of PIOLs, the lens-optic distance shows less variability compared with the cornea-optic distance. Therefore, it is preferable to use measured ACD and subtract it with an 'optic-lens' constant to obtain the value of ELP. For the Artisan/Verisyse lens the optic-lens constant is 0.84 mm. The ICL power is calculated using the Olsen-Feingold formula by using a four variable formula modified by a regression analysis of past results.[3]

Surgical technique

[edit]

The Artisan (Verisyse) lens is implanted under pharmacological miosis. After creating proper incision the lens is grasped with curved holding forceps and inserted. Once in the anterior chamber and while firmly holding the lens with forceps, temporal and nasal iris tissue is enclavated with a special needle. The operation is completed with an iridectomy and the incision is sutured.

The EVO ICL (STAAR® Surgical's phakic IOL) is implanted under pharmacological mydriasis and implanted in the retropupillary position, between the eye's iris and the crystalline lens, using cartridge-injector or forceps. Both eyes can usually be done on the same day.

Steroid antibiotic eye drops are usually prescribed for 2–4 weeks after surgery. Regular follow-ups are recommended.[4]

Risk

[edit]
See also: Cataract surgery § Risk

Though ICL surgery has shown to be effective, it sometimes can result in complications such as:

  • If the ICL is oversized or poorly placed, it can increase eye pressure. Glaucoma may grow as a result of this.
  • If you have high eye pressure for an extended period, you may lose your vision.
  • An ICL can reduce fluid circulation in your eye, putting you at risk for cataracts. This can also happen if the ICL does not fit well or causes chronic inflammation.
  • Cataracts and glaucoma both cause blurry vision. If the lens isn't the right size, you may experience other visual issues such as glare or double vision.
  • Endothelial cells in the cornea are reduced as a result of eye surgery and aging. If the cells die too quickly, a cloudy cornea and vision loss may result.
  • Your retina may detach from its normal position as a result of eye surgery. It's a rare complication that necessitates immediate medical attention.
  • This is another unusual side effect. It has the potential to cause permanent vision loss.
  • You may require additional surgery to remove the lens and correct any issues that have arisen.[9]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Phakic intraocular lens

View on Grokipedia
from Grokipedia
A phakic intraocular lens (pIOL) is a biocompatible artificial lens surgically implanted into the eye to correct refractive errors, primarily moderate to high , without removing or replacing the patient's natural crystalline lens. These lenses, typically made of or collamer (a collagen-polymer hybrid), are positioned in the anterior chamber, fixated to the iris, or placed in the posterior chamber behind the iris, allowing the eye to maintain its natural focusing ability for near vision. Approved by the U.S. (FDA) for nearsightedness correction since the early 2000s, pIOLs serve as an alternative for individuals ineligible for laser-based procedures like due to factors such as thin corneas or extreme refractive errors exceeding -5 to -6 diopters. The development of pIOLs traces back to the , when early anterior chamber designs were introduced by pioneers like Strampelli and Binkhorst, though initial models faced complications like corneal . Advancements in the and led to iris-fixated and posterior chamber variants, with FDA approvals for key models including the iris-fixated Verisyse lens in 2004 and the posterior chamber Visian Implantable Collamer Lens (ICL) in 2005, followed by a toric version for in 2018. Today, posterior chamber pIOLs dominate due to their favorable safety profile, with ongoing refinements like central hole designs (e.g., EVO ICL) to reduce risks such as pupillary block. Surgical implantation involves a small incision under , lens unfolding in the eye, and precise sizing to ensure proper vaulting over the natural lens, typically achieving uncorrected distance of 20/20 or better in 70-90% of cases within the first year. pIOLs offer significant benefits, including reversibility—lenses can be removed if needed—and superior optical quality compared to corneal procedures for high prescriptions, preserving accommodation in younger patients (typically aged 21-45). However, potential complications include endothelial cell loss (1-3% annually), cataract formation (up to 11% over 5-10 years), and rare risks like (0.2-1.7%) or , necessitating lifelong monitoring. Recent studies confirm high efficacy, with safety indices above 1.0 (indicating no vision loss) and minimal refractive predictability errors (±0.5 D in 80-95% of eyes), positioning pIOLs as a reliable option for spectacle independence in suitable candidates.

Overview

Definition and indications

A phakic intraocular lens (pIOL) is an artificial lens made of materials such as or collamer that is surgically implanted into the eye to correct refractive errors while leaving the natural crystalline lens intact. The term "phakic" indicates the presence of the eye's natural lens, distinguishing this procedure from aphakic or pseudophakic implantation, which involves lens removal or replacement. pIOLs are categorized based on their placement within the eye: anterior chamber lenses (angle-supported or iris-fixated), iris-claw lenses, or posterior chamber lenses positioned in the sulcus. The mechanism of pIOLs involves adding refractive power to the eye's optical system in an additive manner, refracting light onto the to correct ametropia without altering the or removing the crystalline lens. This approach preserves the natural lens's accommodative function, allowing for dynamic focusing, particularly beneficial for younger patients. By maintaining the phakic state, pIOLs minimize risks associated with lens extraction and support reversibility, as the implant can potentially be removed. Indications for pIOL implantation primarily include the surgical correction of high refractive errors in patients unsuitable for corneal-based procedures like , such as those with thin corneas. Specifically, they address ranging from -3.0 to -20.0 diopters (D), hyperopia up to +12.0 D, and up to 6.0 D using toric models. Ideal candidates are typically aged 21 to 45 years with stable refraction (less than 0.5 D change per year), an anterior chamber depth of at least 3.0 mm, and adequate endothelial cell density. Recent lens designs have expanded suitability to slightly older patients, up to 55 years in select cases.

History and development

The concept of phakic intraocular lenses (IOLs) emerged in the 1950s, with early anterior chamber designs aimed at correcting high without removing the natural lens. In 1953, Benedetto Strampelli implanted the first minus-power anterior chamber IOL in phakic eyes, followed by José Barraquer's reports in 1959 on similar rigid polymethylmethacrylate (PMMA) lenses positioned in the anterior chamber angle. These pioneering efforts, including contributions from Peter Choyce who refined angle-supported models with thinner haptics in the late 1950s, laid the groundwork but were limited by complications such as corneal endothelial damage and . Development advanced in the and with iris-fixated designs, initially created by Jan Worst for aphakic eyes and adapted for phakic correction by Paul Fechner. The Worst-Fechner biconcave PMMA iris-claw lens, introduced in 1986, marked a significant milestone for iris-fixated phakic IOLs, offering stable refractive outcomes for high despite some endothelial cell loss. Concurrently, angle-supported lenses evolved, with multiple PMMA models developed from the to early , though many were discontinued due to risks like formation; studies in the highlighted design improvements that reduced incidence by optimizing optic-haptic configurations and vaulting. Posterior chamber sulcus-supported lenses were pioneered by in 1986, addressing anterior chamber complications. The 1990s brought material innovations, shifting from rigid PMMA to foldable options like the Implantable Collamer Lens (ICL), a collagen-copolymer material introduced by STAAR Surgical for sulcus placement, enabling smaller incisions and reduced trauma. The ICL received European CE Mark approval in 1997, followed by U.S. FDA approval in 2005 for myopia from -3.00 to -20.00 diopters. Iris-fixated PMMA lenses, such as the Artisan/Verisyse, gained FDA approval in 2004 for myopia correction from -5.00 to -20.00 diopters in suitable anterior chamber depths. Toric versions for astigmatism emerged in the early 2000s, with the Artisan toric approved in Europe around 2003 and ICL toric models gaining FDA approval in 2018 and broader regulatory clearance in the 2010s, enhancing predictability for myopic astigmatism. Global adoption surged in during the 2000s and 2010s, driven by the high prevalence of —up to 80% in young adults in regions like —positioning phakic IOLs as a preferred alternative to procedures for extreme cases. Regulatory expansions continued into the 2020s, with CE Mark for presbyopia-correcting phakic IOLs, such as Ophtec's Artiplus, in 2024, and for the toric version of Artiplus in August 2025, broadening indications for younger patients with refractive errors and near-vision loss. These milestones reflect iterative improvements in and surgical outcomes, leading to the diverse types of phakic IOLs used today.

Types of phakic intraocular lenses

Angle-supported lenses

Angle-supported phakic intraocular lenses (pIOLs) are designed with haptics that fixate directly in the iridocorneal angle of the anterior chamber, typically featuring open-loop or closed-loop configurations to provide stable support without invading the posterior segment. These lenses are inserted into the anterior chamber through a small incision, where they are positioned to rest against the iris root and angle structures, ensuring the optic remains centered for optimal refractive correction. Early models utilized rigid polymethylmethacrylate (PMMA) materials, while later iterations incorporated foldable hydrophilic or hydrophobic acrylic to facilitate smaller incisions and reduce surgical trauma. These lenses typically offer a power range of -10 to +12 diopters, accommodating moderate to high and hyperopia, with optic diameters of 5 to 6 mm to minimize peripheral endothelial contact. They are suitable for eyes with shallower anterior chamber depths, requiring a minimum of 2.8 to 3.0 mm to avoid corneal complications. Unique advantages include easier surgical access via the anterior route and reversibility, as the lens can be removed without disrupting the natural lens or posterior structures. Historically, angle-supported pIOLs trace back to the with early models like the Baikoff ZB, introduced in 1986, which featured PMMA construction and angle-fixated haptics for high correction up to -38 diopters. However, these lenses were associated with higher risks of endothelial cell loss and damage, leading to their discontinuation in many markets, including the , by the early despite design improvements like larger optics to reduce touch, though limited models and advances persist internationally as of 2025. As of 2025, angle-supported pIOLs have limited use globally, with models like Eyecryl PC showing promise in studies, though none are FDA-approved in the . In contrast to posterior types, angle-supported pIOLs provide less vault but simpler anterior placement.

Iris-fixated lenses

Iris-fixated phakic intraocular lenses (pIOLs) are rigid, single-piece devices made from ultraviolet-absorbing polymethylmethacrylate (PMMA), specifically Perspex CQ material with a of 1.49. These lenses feature a convex-concave optic, typically 5.0 mm or 6.0 mm in , supported by an elliptical carrier with two optic clips designed for enclavation into the mid-peripheral iris tissue. The overall length is 8.5 mm, ensuring a stable position without contact to the anterior chamber angle or posterior sulcus. These lenses are implanted into the anterior chamber and fixated directly to the iris stroma through a surgical enclavation process using specialized needles to secure iris folds within the clips. This anterior placement avoids interaction with the or ciliary sulcus, distinguishing it from angle-supported lenses that rely on haptic feet in and sulcus-supported lenses that are flexible and positioned posteriorly. Preoperative of anterior chamber depth (ACD) is essential, with implantation requiring an ACD of at least 3.2 mm to maintain safe clearance from the and crystalline lens. The Verisyse (in the United States) and Artisan models, manufactured by Ophtec, offer a power range from -20 D to +12 D for correcting myopia, hyperopia, and astigmatism up to 2.5 D, with toric variants available for higher cylindrical corrections. The FDA approved the Verisyse/Artisan for myopic corrections from -5 D to -20 D in 2004 under PMA P030028, with subsequent approvals extending to hyperopia and astigmatic models. Unlike the non-foldable, rigid design of these anterior iris-fixated lenses, sulcus-supported pIOLs use injectable silicone or collamer materials for posterior placement. Iris fixation provides stable and resistance to postoperative , as the clips securely to the iris, the eye's most robust tissue, maintaining consistent optic positioning over time. Compared to angle-supported lenses, which can cause endothelial cell concerns due to haptic pressure on the angle, iris-fixated models exhibit a lower risk of formation while carrying a potential for dispersion from iris chafing. In clinical studies, these lenses demonstrate high satisfaction, with rates exceeding 90% reported in FDA trials and follow-up evaluations, alongside long-term explantation rates below 1% within the first decade.

Sulcus-supported lenses

Sulcus-supported phakic intraocular lenses (pIOLs) are posterior chamber devices designed for placement in the ciliary sulcus, offering a minimally invasive option for refractive correction while preserving the natural crystalline lens. These lenses, primarily exemplified by the Visian Implantable Collamer Lens (ICL) family developed by STAAR Surgical, feature foldable haptics that secure the lens in the sulcus without requiring fixation to the iris or angle structures. The design incorporates Collamer, a proprietary biocompatible material composed of a collagen copolymer (hydroxyethyl methacrylate with less than 1% porcine collagen) that integrates ultraviolet-absorbing properties to mimic aspects of the natural lens, enhancing long-term tolerance and reducing inflammatory responses. In the EVO Visian ICL variant, a central 360 µm KS-Aquaport hole facilitates aqueous humor flow, eliminating the need for peripheral iridotomy and significantly lowering the risk of pupillary block and anterior subcapsular cataract formation compared to earlier models without this feature. Placement occurs posterior to the iris and anterior to the crystalline lens within the ciliary sulcus, with a targeted vault (distance between the posterior ICL surface and anterior lens capsule) of 250–750 µm to ensure adequate clearance and minimize complications such as lens touch or iris chafing. The procedure requires a minimum anterior chamber depth (ACD) of 3.0 mm to accommodate safe implantation. Available power ranges include -3.0 to -18.0 D for correction (with reduction up to -20.0 D in select cases), +3.0 to +12.0 D for hyperopia (available internationally under standard Visian ICL labeling; not FDA-approved in the ), and toric options up to 4.0 D of cylinder for management. These lenses stand out for their reversibility, allowing removal or exchange if refractive needs change or complications arise, without altering the corneal structure—a key advantage over ablative procedures. Their high adoption stems from proven efficacy in treating moderate to high , particularly in patients with thin corneas unsuitable for , where over 3 million implants have been performed globally with low complication rates. STAAR Surgical introduced the original Visian ICL in 1993, with U.S. FDA approval for in 2005, toric in 2018, and the EVO model (with central port) for and in 2022; hyperopia indications remain under the standard Visian ICL labeling internationally.

Medical uses

Advantages over other refractive procedures

Phakic intraocular lenses (IOLs) offer significant advantages over corneal refractive procedures such as or PRK, particularly in preserving the natural accommodative function of the eye. By implanting the lens without removing or altering the crystalline lens, phakic IOLs maintain the patient's ability to focus on near objects, which is especially beneficial for younger individuals under 50 years old who rely on accommodation for tasks like reading. This contrasts with refractive lens exchange, where the natural lens is replaced, leading to loss of accommodation and potential induction earlier in life. Another key benefit is the cornea-sparing nature of phakic IOL implantation, which avoids tissue or flap creation associated with laser procedures. This makes phakic IOLs ideal for patients with thin corneas (less than 500 µm) or those at risk of postoperative , as the procedure does not weaken corneal structure or reduce stromal bed thickness. In high cases, where would require excessive corneal removal, phakic IOLs provide a safer alternative without compromising corneal integrity. Phakic IOLs are also reversible, allowing for lens removal or exchange if refractive needs change or complications arise, unlike the permanent corneal alterations from or PRK. This reversibility enhances long-term flexibility and patient reassurance. Additionally, they accommodate a broader refractive range, correcting up to -20 D of , with toric designs effectively managing without inducing higher-order aberrations common in laser reshaping of the peripheral . Postoperative outcomes often include superior contrast sensitivity compared to preoperative levels, contributing to enhanced visual quality in low-light conditions. Phakic IOLs are particularly suitable for athletes or individuals in trauma-prone activities, as the intact eliminates risks like flap dislocation seen in during contact sports. Recent studies indicate that over 97% of patients achieve uncorrected of 20/40 or better, underscoring their efficacy.

Disadvantages and limitations

Phakic intraocular lens (pIOL) implantation is an invasive procedure that involves intraocular surgery, carrying inherent risks such as infection, including the potential for severe complications like , in contrast to non-invasive surface techniques like . Patient eligibility is limited by age, as pIOLs are not approved by the FDA for individuals under 21 years due to unstable during ocular development, and they are generally suitable for patients aged 21-45 years, though options for may allow use in some older individuals. However, as of 2025, specialized phakic IOL designs are emerging for correcting in myopic patients over 45. Dioptric correction capabilities have constraints, with most models accommodating cylindrical corrections up to 4-6 diopters and limited options for extreme hyperopia exceeding +12 diopters, restricting applicability for certain high refractive errors. The procedure is more costly than alternatives like , typically ranging from $4,000 per eye compared to about $2,000 for , and requires specialized surgical expertise and equipment, reducing accessibility in regions without advanced refractive centers. pIOL implantation may necessitate future interventions, such as lens explantation and in some cases, while recent studies indicate that 5-10% of patients require refractive enhancements post-procedure.

Contraindications

Phakic intraocular lens (pIOL) implantation is contraindicated in certain anatomical, ocular, and systemic conditions to minimize risks such as endothelial cell loss, elevated , or poor surgical outcomes. Absolute contraindications preclude surgery due to high risk of irreversible damage, while relative contraindications require careful evaluation and may allow proceeding under specific circumstances.

Absolute Contraindications

  • Insufficient anterior chamber depth (ACD): An ACD less than 3.0 mm for posterior chamber pIOLs (e.g., Visian ICL) or less than 3.2 mm for iris-fixated pIOLs (e.g., Artisan/Verisyse) increases the risk of endothelial decompensation and formation.
  • Low endothelial cell : Preoperative below 2000–2300 cells/mm² (age-dependent, e.g., <2000 cells/mm² for patients over 45 years) heightens the risk of corneal decompensation.
  • Uncontrolled glaucoma or uveitis: Elevated intraocular pressure greater than 21 mmHg or active/recurrent uveitis can lead to exacerbated inflammation or angle closure.
  • Pregnancy or breastfeeding: Hormonal fluctuations may cause unstable refraction, making accurate lens power calculation unreliable.
  • Iris anomalies for iris-fixated pIOLs: Conditions such as aniridia, severe iris atrophy, coloboma, or peaked pupils prevent secure lens fixation.
  • Inadequate sulcus anatomy for posterior chamber pIOLs: Anterior chamber angle less than grade II (gonioscopy) risks pupillary block or lens malposition.

Relative Contraindications

  • Autoimmune diseases: Conditions like rheumatoid arthritis may impair postoperative healing and increase inflammation risk.
  • Systemic diabetes with poor control: Uncontrolled hyperglycemia can affect wound healing and heighten infection or retinopathy risks.
  • Ocular surface disorders: Severe dry eye or compromises corneal integrity and refractive stability.
  • Prior corneal surgery: History of procedures like may alter corneal biomechanics, increasing ectasia risk.
  • Age extremes: Patients under 21 years or over 45 years face higher risks due to refractive instability or reduced endothelial reserve, respectively.
  • Unrealistic patient expectations: Individuals unable to comprehend potential outcomes or commit to follow-up may not achieve satisfactory results.
These contraindications are identified through preoperative assessments such as gonioscopy, endothelial cell counting, and anterior segment imaging to ensure patient safety.

Patient selection and preoperative evaluation

Eligibility criteria

Eligibility for phakic intraocular lens (IOL) implantation is determined by a combination of refractive, anatomical, and health-related factors to ensure safety and efficacy. Ideal candidates are typically adults aged 21 to 45 years with stable refractive errors, particularly moderate to high , who seek spectacle independence and are not suitable for corneal refractive procedures like due to thin corneas or other limitations. Patients must demonstrate refractive stability, defined as no change greater than 0.5 diopters (D) in spherical equivalent over the past year, to minimize the risk of postoperative shifts; this stability is best achieved after age 21 when myopic progression typically plateaus. Anatomical suitability is critical, requiring an anterior chamber depth (ACD) of at least 3.0 mm to accommodate the lens without compromising the natural crystalline lens or endothelium. A healthy corneal endothelium, with a cell density of at least 2,000 cells/mm² (or higher, such as >2,500 cells/mm² in younger patients), is essential to prevent long-term . The anterior segment must be clear, free from active infections, , or other pathologies that could interfere with lens placement or increase complication risks. By 2025 guidelines, eligibility has expanded to include low greater than -3.0 D, particularly for patients intolerant to contact lenses or preferring the reversibility of phakic IOLs over permanent corneal , aided by AI-based sizing tools for precise fitting. Candidates should be motivated for the procedure, understanding its potential for lifelong monitoring despite reversibility, and have controlled systemic conditions without active ocular or autoimmune diseases. Lifestyle factors, such as participation in contact sports, are generally compatible due to the intraocular positioning, which offers protection from corneal trauma compared to surface procedures. This contrasts briefly with contraindications, which strictly exclude patients with shallow ACD or endothelial compromise.

Diagnostic assessments

Preoperative diagnostic assessments are essential to evaluate the anterior and posterior segments of the eye, ensuring anatomical suitability and minimizing risks such as endothelial cell loss, formation, and in patients considered for phakic intraocular lens (pIOL) implantation. These evaluations focus on precise measurements of ocular dimensions and tissue health, guiding lens selection and surgical planning while identifying contraindications like corneal or inadequate anterior chamber depth. Biometry is a cornerstone of preoperative assessment, typically performed using devices such as the IOLMaster 700 optical biometer or Pentacam Scheimpflug tomographer to measure anterior chamber depth (ACD), white-to-white (WTW) corneal diameter, and crystalline lens rise (CLR). The IOLMaster provides accurate ACD measurements, which are critical for assessing space availability for pIOL placement, while the Pentacam offers detailed WTW and CLR data to predict vault and avoid iris or lens touch. These parameters help determine lens size, with WTW guiding sulcus-supported pIOL fitting and CLR indicating potential vault instability if elevated. Endothelial evaluation relies on specular microscopy to quantify corneal endothelial cell density (ECD) and morphology, establishing a baseline for monitoring postoperative cell loss, which can exceed 10-20% in the first year after pIOL implantation. Preoperative ECD should generally exceed 2000 cells/mm² to ensure long-term corneal health, with manual counting methods recommended for accuracy in borderline cases. This non-contact technique visualizes the hexagonal mosaic of endothelial cells, flagging risks from anterior chamber pIOLs that may accelerate . Ultrasound biomicroscopy (UBM) is employed to visualize posterior structures, measuring sulcus-to-sulcus (STS) diameter and assessing angle configuration for iris-fixated or sulcus-supported pIOLs. High-frequency UBM (20-50 MHz) provides cross-sectional images of the ciliary sulcus and iris-lens relations, improving sizing accuracy over external measurements and reducing vault-related complications like pupillary block. It is particularly valuable in opaque media or for confirming angle patency, with STS values typically ranging 11.5-13.0 mm in suitable candidates. Corneal topography, often via Placido disc or Scheimpflug imaging, is used to detect subclinical or irregular , contraindicating pIOL in eyes with or . Abnormal topographic patterns, such as inferior steepening, must be ruled out to prevent postoperative visual aberrations. measures scotopic pupil diameter to assess risks, as enlarged pupils (>7 mm) may increase glare or halos from optic in pIOLs. Preoperative testing under mesopic conditions informs patient counseling on potential dysphotopsia. Refraction under ensures accurate manifest error determination, minimizing accommodation artifacts in young myopes. This is complemented by to evaluate retinal health, excluding peripheral tears or degeneration that could worsen with changes post-surgery. Recent advancements include AI-based tools like ICL Guru, which integrate biometry data for vault prediction, with over 86% of predictions within 0.2 mm of actual vault and enhancing precision in posterior chamber pIOLs. These models analyze ACD, WTW, and STS to forecast postoperative outcomes, reducing revision rates.

Lens power calculation

Measurement techniques

White-to-white (WTW) distance, a key parameter for assessing the haptic footprint in phakic intraocular lens (IOL) implantation, is typically measured using for external corneal diameter or optical methods such as anterior segment (AS-OCT). AS-OCT provides high-resolution imaging for more precise internal measurements compared to , which may overestimate due to corneal compression. Average WTW values in candidates for phakic IOL range from 11.5 to 12.5 mm, with studies reporting means around 11.8 ± 0.4 mm using devices like the IOLMaster. Anterior chamber depth (ACD) and vault prediction are evaluated using AS-OCT or ultrasound biomicroscopy (UBM) to measure anterior-posterior distances, ensuring adequate space for lens placement without endothelial compromise. AS-OCT excels in non-contact visualization of the anterior segment, while UBM offers detailed imaging of posterior structures. Postoperative vault, the distance between the phakic IOL and crystalline lens, is targeted at 250-750 µm to optimize safety and efficacy, as deviations can lead to complications like formation. Scleral spur-to-scleral spur (STS) distance and ciliary sulcus dimensions, critical for sulcus-supported phakic IOLs, are primarily assessed via UBM, which directly measures posterior chamber width with high-frequency probes. This technique is essential for accurate sizing in posterior chamber lenses, as STS provides a more reliable internal metric than external WTW approximations. Nomograms for phakic IOL size selection integrate WTW, ACD, and patient age to predict optimal fit, particularly for models like the V4c implantable collamer lens (ICL), available in sizes from 11.6 to 13.2 mm. These tools, often manufacturer-specific, adjust for anatomical variations to achieve desired vault. Recent advancements as of 2025 incorporate (AI) into measurement workflows, enhancing vault prediction accuracy and reducing sizing errors to below 10% in multimodal systems analyzing AS-OCT and UBM data. Corneal assessment via pachymetry ensures sufficient thickness, ideally exceeding 500 µm centrally, to support surgical tolerance and postoperative healing in phakic IOL candidates. Iris and angle evaluation through gonioscopy confirms angle patency and openness, preventing risks like pupillary block in anterior chamber lenses.

Formulas and nomograms

The power calculation for phakic intraocular lenses (IOLs) relies on theoretical and empirical formulas that account for the eye's optical parameters to achieve the desired postoperative while preserving the natural crystalline lens. A foundational approach uses vergence principles and the formula to adjust the spectacle to the corneal plane and then to the IOL position: Pvertex=P1−d⋅PP_{\text{vertex}} = \frac{P}{1 - d \cdot P} where dd is the vertex distance in meters and PP is the power in diopters; adjustments are made for the IOL's position in the anterior or posterior chamber to avoid over- or under-correction. One standard method is the Van der Heijde equation, which calculates IOL power based on corneal power (), spectacle correction at the corneal vertex (Ps′P_s'), effective lens position (dd), and the of aqueous (n=1.336n = 1.336): FIOL=nn−K⋅d+Ps′−d−nn−K⋅dF_{\text{IOL}} = \frac{n}{n - K \cdot d} + P_s' - d - \frac{n}{n - K \cdot d} This vergence-based formula is widely used for anterior and iris-fixated lenses, often implemented in manufacturer software. Manufacturer-specific formulas, such as that for the STAAR Surgical Implantable Collamer Lens (ICL), build on this by incorporating additional biometric factors like anterior chamber depth (ACD), white-to-white (WTW) distance, and patient age to estimate effective lens position () and vault. The STAAR ICL formula is a modified vertex method, expressed generally as PICL=f(manifest refraction,ACD,ELP)P_{\text{ICL}} = f(\text{manifest refraction}, \text{ACD}, \text{ELP}), where ELP is predicted from ACD and WTW to optimize lens sizing and power, reducing risks like formation. This online integrates keratometry, axial length, and age-related accommodative changes for precise dioptric selection. Nomograms serve as graphical tools for simplifying these calculations, plotting preoperative against key to select lens power and size. For iris-fixated phakic IOLs, the Fechner nomogram (associated with early Worst-Fechner designs) correlates spherical equivalent , keratometry, and ACD to predict IOL power, aiding in the correction of high up to -20 D. Similarly, the Van der Heijde , widely used for anterior chamber and iris-claw lenses, bases power on spectacle correction vertex-adjusted to the , corneal power, and ACD, providing a quick reference for without full computational software. These nomograms emphasize empirical adjustments for lens position to minimize refractive surprises. Adaptations of established pseudophakic formulas like SRK/T and Holladay II have been explored for phakic applications by modifying the effective lens position to account for the intact crystalline lens, using ray-tracing to simulate the combined optical system. The SRK/T formula, for instance, incorporates surgeon factors and theoretical eye models adjusted for phakic , while Holladay II integrates higher-order aberrations and posterior corneal for improved accuracy in myopic eyes. Validation through ray-tracing software, such as OKULIX, confirms these adaptations by modeling light paths and predicting postoperative with errors under 0.5 D in most cases. As of 2025, (AI)-optimized models represent a significant advance, with algorithms like those developed by Jiang et al. generating novel nomograms for phakic IOL power that integrate large datasets of biometric and refractive outcomes. These AI tools, such as stacking ensemble models for ICL calculation, enhance prediction accuracy by reducing mean absolute errors in refractive outcomes, particularly in low-to-moderate , and minimize hyperopic shifts through better vault forecasting—achieving significant improvements in refractive predictability compared to traditional methods in validation studies. Sources of error in these calculations primarily stem from measurement inaccuracies, notably in axial length (AL), where a ±0.1 mm deviation typically induces a 0.25 D refractive error due to the eye's optical scaling (approximately 2.5 D per 1 mm in average eyes). Ray-tracing software is routinely used for validation to quantify such impacts and refine formulas, ensuring clinical reliability.

Surgical technique

Preoperative preparation

Preoperative preparation for phakic intraocular lens (PIOL) implantation begins with comprehensive patient counseling to ensure . Patients receive detailed discussions on potential risks, including formation, endothelial cell loss, and , as well as alternatives such as laser refractive surgery or spectacle correction. This process emphasizes establishing realistic expectations regarding visual outcomes, such as the persistence of in older candidates, and may include simulations using to preview postoperative vision quality. A standardized regimen is initiated to minimize and risks. Typically, topical antibiotics and corticosteroids are prescribed starting one week prior to to prepare the ocular surface, while cycloplegic agents like are used in the days leading up to the procedure to stabilize refraction measurements and facilitate accurate lens power confirmation. For posterior chamber PIOLs, such as the Implantable Collamer Lens (ICL), peripheral iridotomy is performed 1-2 weeks preoperatively to prevent pupillary block, ensuring aqueous humor flow. Lens selection is finalized based on preoperative biometry, including anterior chamber depth (minimum 3.0 mm for ICL models) and sulcus-to-sulcus diameter measurements obtained via biomicroscopy. The appropriate model—such as Visian ICL for up to -20.0 D or for iris-fixated placement—is chosen, with size customized to achieve a vault of 250-750 microns post-implantation. For toric lenses correcting , the axis is marked preoperatively using reference images, and lenses are pre-sterilized by the manufacturer in sterile packaging to maintain integrity until loading. Backup lenses in varying sizes and powers are prepared to address any intraoperative adjustments. On the day of surgery, patients adhere to anesthesia protocols, including fasting for at least 6-8 hours to mitigate aspiration risks under topical or mild intravenous sedation. A pupillary dilation test is conducted using tropicamide drops to assess iris dynamics and confirm no contraindications like synechiae, ensuring safe lens insertion. Facility preparation ensures optimal conditions, with the operating configured for coaxial illumination to enhance visibility during anterior segment maneuvers. Instruments are sterilized, and the surgical field is draped, with backup available for any crystalline lens complications.

Intraoperative procedure

The intraoperative procedure for phakic intraocular lens (IOL) implantation is performed under topical , often supplemented with mild intravenous to ensure patient comfort and minimize movement, typically lasting 10 to 15 minutes per eye. A small 1 mm peripheral corneal incision is first created at the limbus to allow for intracameral anesthetic injection and viscoelastic material introduction, which maintains anterior chamber depth and protects the crystalline lens. This is followed by a primary 2.8 to 3.2 mm clear corneal or scleral tunnel incision for lens delivery, with emerging 2025 techniques incorporating assistance to enhance incision precision and reduce trauma. For posterior chamber (sulcus-supported) or anterior chamber (angle-supported) phakic IOLs, such as the Implantable Collamer Lens (ICL), the foldable lens is loaded into a proprietary injector cartridge shortly before insertion to prevent unfolding or damage. The lens is then advanced through the incision into the anterior chamber, where it unfolds slowly; for sulcus placement, a manipulator tool tucks the haptics behind the iris to position the optic in the posterior chamber anterior to the crystalline lens. In iris-fixated designs, manual enclavation clips the lens haptics into stromal tunnels within the iris periphery. For toric lenses correcting , the implant is rotated intraoperatively to align with the preoperative axis marking on the . Intraoperative vault—the distance between the phakic IOL and the crystalline lens—is confirmed using biomicroscopy (UBM) or anterior segment (AS-OCT) to ensure adequate clearance (typically 250–750 μm) and prevent contact or excessive pressure. The viscoelastic is then thoroughly removed via bimanual irrigation and aspiration with to avoid postoperative pressure elevation, taking care not to irrigate directly through any central lens port in models like the EVO ICL. The incisions are sealed by stromal hydration to promote self-sealing, with sutures rarely required due to the small size. The procedure concludes with verification of chamber stability and lens centration before the eye is shielded.

Postoperative care

Patients should limit or avoid screen use (e.g., phones, computers, TV) in the initial days post-surgery to reduce eye strain, dryness, and discomfort, gradually resuming moderate use as tolerated without symptoms, typically after the first week.

Complications and risks

Intraoperative risks

During phakic intraocular lens (pIOL) implantation, chamber collapse represents a significant intraoperative , particularly in highly myopic patients with floppy globes, where loss of viscoelastic material or excessive manipulation can lead to shallowing of the anterior chamber and potential contact between the lens and , risking endothelial cell damage. This complication is mitigated by injecting to maintain chamber depth or using a temporary slipknot suture at the incision site to stabilize the anterior chamber during lens enclavation. Lens malposition, including decentration, tilt, or incorrect rotation during insertion, can occur due to improper handling or inadequate anterior chamber maintenance, with an overall intraoperative lens turnover rate of approximately 1.8% reported in posterior chamber pIOL cases such as implantable collamer lenses (ICLs). For toric pIOLs, axis misalignment exceeding 5° during placement reduces astigmatic correction efficacy by over 15%, though modern systems have lowered such errors to under 1° in experienced hands. If extreme vaulting (e.g., >550 µm) is detected intraoperatively via anterior segment , immediate explantation and lens exchange may be required to prevent iris or endothelial trauma. Iris trauma during enclavation is a specific concern in iris-fixated pIOLs, with an incidence of or necessitating re-enclavation in about 2% of cases, often due to inadequate tissue grasping rather than direct surgical injury. Haptic breakage in foldable pIOLs is rare, typically from forceful cartridge loading or injector malfunction, and is managed by aborting implantation and using a lens. Instrument-related corneal abrasions arise from speculum or contact, with incidences mirroring general anterior segment at around 0.1-0.2%, and are prevented through meticulous draping and . Suprachoroidal hemorrhage, though uncommon in pIOL , has a reported incidence of approximately 0.1%, triggered by sudden spikes during incision or viscoelastic injection, and demands prompt chamber reformation with hyperosmotic agents if detected. As of 2025, advancements in automated injectors and real-time have reduced overall intraoperative complication rates by up to 50% compared to earlier techniques, enhancing precision in lens delivery and positioning.

Postoperative complications

Postoperative complications following phakic intraocular lens (pIOL) implantation primarily involve early recovery issues within the first 1-3 months, with most resolving through conservative management. In the first week, typical side effects include light inflammation, light sensitivity, foreign body sensation, and blurred vision; these mild effects are common and usually subside quickly. Inflammation, such as anterior or cystoid , occurs in approximately 1-5% of cases, often due to surgical trauma or retained viscoelastic material. These are typically mild and managed with topical nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids to reduce anterior chamber reaction and prevent macular involvement. Infection, particularly , is a rare but serious complication with an incidence of about 0.017% (1 in 6,000 cases), usually presenting within days of surgery with symptoms like pain, redness, and . Prophylaxis includes perioperative topical antibiotics, and prompt treatment with intravitreal antibiotics is essential to preserve vision. Transient (IOP) elevation is common in the early postoperative period, affecting 5-7% of patients, often from steroid-induced response or incomplete viscoelastic removal. This is managed with topical beta-blockers or inhibitors, with resolution expected within days to weeks upon tapering steroids. Refractive surprises, including undercorrection or hypercorrection, necessitate enhancement procedures in roughly 5% of cases within the first 3 months, typically addressed via laser vision correction once stability is confirmed. Visual disturbances like halos and , stemming from optic or light scatter, affect a notable portion of patients initially but resolve in over 90% through neuroadaptation within months. Recent studies indicate reduced incidence and severity with central port designs, such as the EVO ICL, due to improved aqueous flow and minimized pupillary block. Monitoring is crucial during early recovery, with follow-up visits scheduled at 1 day, 1 week, 1 month, and beyond, including daily checks in the first week for high-risk cases. Slit-lamp examination assesses vault (ideal 250-750 μm), , and IOL position to detect issues promptly.

Long-term risks

One of the primary long-term risks associated with phakic intraocular lenses (IOLs) is the development of anterior subcapsular cataracts, particularly in posterior chamber models where the lens may contact the natural crystalline lens. In older designs without a central port, cataract formation rates range from 2% to 7% at 5 years postoperatively, increasing to approximately 18% for visually significant cases requiring intervention at 10 years. However, newer aquaport (central hole) models, such as the EVO-ICL, have substantially reduced this risk to less than 1% over 5 years due to improved aqueous humor flow and reduced lenticular touch. Endothelial cell loss represents another chronic concern, with initial annual rates of 1% to 2% in the first few years post-implantation, stabilizing thereafter to approach the natural age-related decline of about 0.6% per year. This loss is more pronounced in angle-supported and iris-fixated IOLs, where rates can reach 1.8% annually over extended follow-up, compared to posterior chamber lenses that show total losses of around 5% to 8% at 10 years. Clinical guidelines recommend monitoring endothelial cell density annually, with explantation considered if cumulative loss exceeds 20% to prevent corneal . Glaucoma risk arises primarily from angle closure in posterior chamber IOLs when vaulting exceeds 1000 µm, leading to pupillary block or excessive iris-lens contact; this is rare in long-term cohorts. Iris-fixated models carry a of pigmentary dispersion , which can elevate through iris chafing, occurring in up to 15% of cases over 5 to 10 years and potentially requiring lens explantation. necessitating medication develops in about 13% of patients at 10 years, though progression to frank remains rare with proper vault management. Retinal detachment is a rare but serious long-term risk, with incidences reported from 0.2% to 1.7% over follow-up periods, particularly in highly myopic patients. Additional long-term issues include lens opacification and decentration, contributing to an overall explantation rate of around 1% to 2% at 10 years across IOL types, often due to chronic inflammation or misalignment. Longitudinal studies as of indicate high device retention, with approximately 94% to 95% of posterior chamber IOLs remaining in place at 15 years, reflecting improvements in material and surgical precision. Mitigation strategies emphasize routine postoperative surveillance, including annual specular microscopy for endothelial counts and anterior segment to assess vaulting, with prophylactic peripheral iridotomy recommended for at-risk eyes to prevent angle closure.

Outcomes and recent advances

Clinical efficacy and safety data

Clinical studies demonstrate high of phakic intraocular lenses (pIOLs), particularly posterior chamber models like the Implantable Collamer Lens (ICL), in correcting moderate to high . In the U.S. FDA for the EVO ICL (n=629 eyes), 90.5% of eyes achieved refractive predictability within ±0.5 D of the target manifest refraction spherical equivalent at 6 months postoperatively. Uncorrected distance (UDVA) reached 20/20 or better in 80.1% of eyes, with 99.4% achieving 20/40 or better among those with preoperative corrected distance (CDVA) of 20/20 or better. A of ICL implantation across multiple studies confirmed these outcomes, with approximately 60% of eyes attaining UDVA of 20/20 or better at 5 years or longer follow-up. Safety profiles are favorable with modern pIOL designs, showing minimal impact on and low rates of formation. The same FDA trial reported a mean endothelial cell loss of 2.3% at 6 months, with 97.3% of eyes experiencing ≤10% loss and no cases dropping below 1000 cells/mm². Long-term data indicate an annual endothelial cell loss of 1.0-2.3% beyond the initial postoperative period, resulting in approximately 9-11.5% total loss at 5 years. incidence remains low at <2%, with the FDA trial documenting only 0.2% nuclear cataracts and a broader reporting 0.3% asymptomatic anterior subcapsular cataracts over up to 10 years, primarily linked to inadequate vault in high-risk cases. Patient satisfaction exceeds 95%, with 98.3% of recipients reporting overall satisfaction in functional outcome studies and 99% in ICL-specific trials. Meta-analyses up to 2025 highlight pIOL advantages in visual quality for high , including superior contrast sensitivity compared to . A Cochrane review of randomized controlled trials (n=228 eyes, myopia -6.0 to -20.0 ) found phakic IOLs resulted in significantly better contrast sensitivity (P<0.001) and lower loss of best spectacle-corrected (OR 0.41, 95% CI 0.33-0.51) at 12 months versus procedures. Toric pIOL models effectively address , with 76.9% of eyes achieving correction within ±0.5 of target in spherical equivalent and mean residual reduced by 73.6% to 0.51 postoperatively. The European Registry of Quality Outcomes for and Refractive Surgery (EUREQUO) provides long-term validation, showing significant UDVA improvements post-pIOL implantation for high across thousands of cases, with stable refractive outcomes and low complication rates over multi-year follow-up. Compared to surface like PRK, pIOLs offer superior efficacy in patients with thin corneas, avoiding corneal tissue removal while maintaining reversibility as a key advantage over permanent laser techniques. In the EVO ICL FDA trial subset (n=500+), 98.4% of eyes achieved a safety index greater than 1.0, underscoring robust preservation of CDVA.

Innovations as of 2025

As of 2025, phakic intraocular lenses (pIOLs) have seen significant advancements driven by (AI) integration, refined lens designs, and procedural enhancements, marking a in their application for refractive correction. These innovations address longstanding challenges such as precise sizing, management, and expanded indications, improving safety and efficacy for a broader . AI tools have revolutionized preoperative planning, particularly in lens sizing and vault prediction to minimize complications like cataract formation or glaucoma. Platforms such as the ICL Guru by utilize algorithms to analyze multimodal imaging data, achieving a (MAE) of 66.3 µm in vault predictions for certain lens sizes, which enhances precision over traditional nomograms, especially in off-label or borderline cases. This approach reduces vault-related errors by integrating models trained on large datasets of anterior segment parameters, leading to more predictable postoperative outcomes in implantable collamer lens (ICL) procedures. Design innovations focus on multifocal and extended-depth-of-focus (EDOF) phakic IOLs to correct alongside refractive errors, including hybrid toric models for . For instance, foldable multifocal iris-fixated phakic IOLs have demonstrated six-month safety and effectiveness, with mean binocular uncorrected near (UNVA) of 0.02 logMAR and 83% spectacle independence. These lenses feature aspheric optics to reduce halos and glare, expanding options for presbyopic patients unsuitable for corneal procedures. Additionally, posterior chamber phakic IOLs now accommodate higher hyperopic corrections. Femtosecond laser technology has been investigated for incision creation in ICL implantation. Comparative studies show no significant differences in endothelial cell loss or refractive predictability between femtosecond-assisted and manual techniques at six months, though femtosecond methods may induce higher initial astigmatism. New approvals in 2025 include the Loong Crystal PR phakic IOL in China, featuring a zero-spherical-aberration design and stable arc height for improved visual quality in myopic patients aged 18-45. The TECNIS Phakic IOL, approved in Europe in 2024, targets young adults with low-to-moderate myopia (down to -2.5 D), broadening access for milder refractive errors. Surgical enhancements incorporate AI-guided diagnostics for candidate selection and blended vision strategies in presbyopia cases, optimizing monovision-like outcomes without compromising binocular function. Robotic assistance, while more established in , is emerging in refractive contexts through integrated systems that automate docking and fragmentation, potentially adaptable for phakic IOL insertion to further minimize tremor and enhance haptic placement. Looking ahead, upgradable phakic IOLs offer reversibility for lifecycle management, allowing lens exchange as patient needs evolve, such as in younger cohorts anticipating . A 2023 clinical trial evaluated phakic IOLs for refractive in children and adolescents with high , showing promising efficacy as an alternative for noncompliant patients. These developments underscore a shift toward personalized, long-term refractive solutions.

References

  1. https://www.fda.gov/medical-devices/phakic-intraocular-lenses/what-are-phakic-lenses
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC7856940/
  3. https://eyewiki.org/Phakic_Intraocular_Lenses
  4. https://pubmed.ncbi.nlm.nih.gov/38059758/
  5. https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1438569/full
  6. https://my.clevelandclinic.org/health/articles/25099-iols-intraocular-lenses
  7. https://www.ncbi.nlm.nih.gov/books/NBK560763/
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC5139554/
  9. https://www.sciencedirect.com/science/article/abs/pii/S0886335010012058
  10. https://www.opticianonline.net/cpd-archive/6911/
  11. https://pubmed.ncbi.nlm.nih.gov/10202702/
  12. https://crstodayeurope.com/articles/2007-sep/0907_19-php/
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC3885970/
  14. https://www.staar.com/news/2010/new-visianr-icl-products-gain-ce-mark-approval
  15. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p030028
  16. https://www.reviewofophthalmology.com/article/where-are-the-toric-phakic-lenses
  17. https://crstoday.com/articles/2009-oct/crst1009_05-php
  18. https://eyewire.news/news/ophtec-receives-ce-mark-approval-for-artiplus-phakic-iol-for-presbyopia
  19. https://www.ophtec.com/blog/ce-mark-for-artiplus-toric-and-precizon-go-toric-marks-a-new-chapter-in-ophtecs-portfolio
  20. https://jamanetwork.com/journals/jamaophthalmology/fullarticle/1779719
  21. https://journals.lww.com/egos/_layouts/15/oaks/journals/downloadpdf.aspx?an=01735167-202507000-00002
  22. https://europe.ophthalmologytimes.com/view/advances-phakic-angle-supported-iols-futures-bright
  23. https://www.accessdata.fda.gov/cdrh_docs/pdf3/p030028c.pdf
  24. https://www.ophtec.com/blog/artisan-phakic-iols
  25. https://crstodayeurope.com/articles/2010-feb/the-safety-of-iris-fixated-designs/
  26. https://www.reviewofophthalmology.com/article/master-the-complications-of-phakic-lenses
  27. https://coflent.com.ec/wp-content/uploads/2023/08/145.pdf
  28. https://www.staar.com/products/visian-icl
  29. https://eyewiki.org/Implantable_Collamer_Lens
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC7856930/
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC6267497/
  32. https://evo.staar.com/
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC9872858/
  34. https://www.accessdata.fda.gov/cdrh_docs/pdf3/P030016C.pdf
  35. https://www.icanseeclearly.com/evo-visian-icl-implantable-contact-lens
  36. https://us.discovericl.com/
  37. https://investors.staar.com/news-and-events/press-releases/2022/03-28-2022-092935988
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC12534635/
  39. https://www.reviewofophthalmology.com/article/phakic-iols-tips-and-techniques
  40. https://www.escrs.org/channels/eurotimes-articles/phakic-iols-for-myopia-and-presbyopia/
  41. https://ophthalmologymanagement.com/issues/2013/february/thin-corneas-in-lasik-how-low-can-you-go/
  42. https://www.ophthalmologytimes.com/view/for-younger-patients-with-midrange-myopia-consider-phakic-iols
  43. https://crstodayeurope.com/articles/2020-sept/phakic-iols-clinical-guidelines-and-best-practices/
  44. https://iovs.arvojournals.org/article.aspx?articleid=2381027
  45. https://pure.johnshopkins.edu/en/publications/change-of-contrast-sensitivity-after-implantation-of-implantable-
  46. https://www.aao.org/education/headline/choosing-among-refractive-surgery-options-to-meet-
  47. https://pubmed.ncbi.nlm.nih.gov/18031820/
  48. https://pmc.ncbi.nlm.nih.gov/articles/PMC7301210/
  49. https://www.fda.gov/medical-devices/phakic-intraocular-lenses/are-phakic-lenses-you
  50. https://www.uofmhealth.org/our-care/specialties-services/phakic-intraocular-lenses-iols-or-implantable-contact-lenses-icls
  51. https://www.nature.com/articles/eye2012235
  52. https://www.nvisioncenters.com/iol/phakic-surgery-cost/
  53. https://www.aao.org/eyenet/article/long-term-impact-of-phakic-iols-in-myopic-eyes
  54. https://escrs.org/channels/eurotimes-articles/phakic-iol
  55. https://www.accessdata.fda.gov/cdrh_docs/pdf3/p030016c.pdf
  56. https://www.aaojournal.org/article/S0161-6420(09)00908-7/fulltext
  57. https://crstoday.com/articles/may-2025/phakic-iols-in-2025
  58. https://crstoday.com/articles/sept-2020/phakic-iols-clinical-guidelines-and-best-practices
  59. https://pubmed.ncbi.nlm.nih.gov/37568866/
  60. https://pubmed.ncbi.nlm.nih.gov/25363849/
  61. https://pubmed.ncbi.nlm.nih.gov/38512912/
  62. https://www.aao.org/assets/223be21c-1c5d-47e2-ac3f-700f6ec30816/635774889629500000/specular-microscopy-guidelines-for-phakic-iols-comment-document-september-2015-pdf
  63. https://pubmed.ncbi.nlm.nih.gov/15019381/
  64. https://pubmed.ncbi.nlm.nih.gov/21050711/
  65. https://pubmed.ncbi.nlm.nih.gov/36071422/
  66. https://pubmed.ncbi.nlm.nih.gov/26432118/
  67. https://eyewiki.aao.org/Phakic_Intraocular_Lenses
  68. https://eyewiki.aao.org/Pupil_Measurements_prior_to_Refractive_Surgery
  69. https://www.aao.org/Assets/8fe35182-77aa-4cc5-a9f8-cb1ecf300733/636492821908400000/refractive-ppp-final-12-19-17-pdf
  70. https://www.aao.org/Assets/229c8c01-0e3f-40e4-b866-a9ec7fd882a7/638070751054870000/refractive-errors-ppp-pdf
  71. https://pmc.ncbi.nlm.nih.gov/articles/PMC12205027/
  72. https://pubmed.ncbi.nlm.nih.gov/40584254/
  73. https://pubmed.ncbi.nlm.nih.gov/39223843/
  74. https://pubmed.ncbi.nlm.nih.gov/15691557/
  75. https://pubmed.ncbi.nlm.nih.gov/26999937/
  76. https://pmc.ncbi.nlm.nih.gov/articles/PMC12468152/
  77. https://www.nature.com/articles/s41598-024-64390-0
  78. https://pubmed.ncbi.nlm.nih.gov/31174990/
  79. https://eandv.biomedcentral.com/articles/10.1186/s40662-020-00208-0
  80. https://journals.lww.com/egos/fulltext/2025/04000/correlation_between_sulcus_measurement_for_phakic.5.aspx
  81. https://link.springer.com/article/10.1007/s40123-023-00844-4
  82. https://journals.healio.com/doi/10.3928/1081597X-20230605-01
  83. https://aes.amegroups.org/article/view/8271/html
  84. https://www.sciencedirect.com/topics/medicine-and-dentistry/corneal-pachymetry
  85. https://www.sciencedirect.com/science/article/abs/pii/S0886335006011175
  86. https://crstodayeurope.com/articles/2011-oct/biometry-calculations-for-phakic-iols/
  87. https://entokey.com/phakic-intraocular-lens-power-calculations/
  88. https://bio-protocol.org/exchange/minidetail?id=4795951&type=30
  89. https://www.facoelche.com/pdf/nomograma_van_der_heijde.pdf
  90. https://pubmed.ncbi.nlm.nih.gov/35916990/
  91. https://eyewiki.org/Biometry_for_Intra-Ocular_Lens_%28IOL%29_Power_Calculation
  92. https://bjo.bmj.com/content/107/4/483
  93. https://journals.lww.com/kjop/fulltext/2025/01000/ai_for_a_clear_eye__revolutionizing_refractive.23.aspx
  94. https://eandv.biomedcentral.com/articles/10.1186/s40662-023-00338-1
  95. https://www.ncbi.nlm.nih.gov/books/NBK599551/
  96. https://emedicine.medscape.com/article/1228447-images
  97. https://www.fda.gov/medical-devices/phakic-intraocular-lenses/during-after-surgery
  98. https://pmc.ncbi.nlm.nih.gov/articles/PMC11329818/
  99. https://clinicaloptometry.scholasticahq.com/article/75436-posterior-chamber-phakic-intraocular-lens-indications-contraindications-technique-and-postoperative-management
  100. https://crstoday.com/articles/phakic-iol-surgery/perfect-your-surgical-technique-with-these-intraoperative-pearls
  101. https://escrs.org/channels/eurotimes-articles/refractive-surgery-with-the-modern-posterior-chamber-phakic-iol
  102. https://youngmdconnect.com/articles/2023-may-supplement/phakic-iol-surgery
  103. https://americanrefractivesurgerycouncil.org/icl-recovery-vision-correction-timeline/
  104. https://www.reviewofophthalmology.com/article/the-dos-and-donand8217ts-of-phakic-lens-implants-44218
  105. https://pmc.ncbi.nlm.nih.gov/articles/PMC9587946/
  106. https://pmc.ncbi.nlm.nih.gov/articles/PMC7137703/
  107. https://pubmed.ncbi.nlm.nih.gov/24612053/
  108. https://webeye.ophth.uiowa.edu/eyeforum/cases/152-perioperative-corneal-abrasions.htm
  109. https://crstodayeurope.com/articles/2013-may/a-surgical-nightmare-suprachoroidal-hemorrhage/
  110. https://pmc.ncbi.nlm.nih.gov/articles/PMC12319018/
  111. https://pmc.ncbi.nlm.nih.gov/articles/PMC10019354/
  112. https://www.nature.com/articles/eye2011187
  113. https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2500162
  114. https://www.escrs.org/channels/eurotimes-articles/when-is-it-time-to-remove-a-phakic-iol
  115. https://journals.lww.com/jcrs/fulltext/2021/06000/implantation_of_an_iris_fixated_phakic_intraocular.11.aspx
  116. https://www.accessdata.fda.gov/cdrh_docs/pdf3/P030016S035B.pdf
  117. https://www.researchgate.net/publication/303891955_Meta-analysis_and_review_Effectiveness_safety_and_central_port_design_of_the_intraocular_collamer_lens
  118. https://www.sciencedirect.com/science/article/abs/pii/S0002939406002571
  119. https://garyfostermd.com/phakic-iol/
  120. https://pmc.ncbi.nlm.nih.gov/articles/PMC10726981/
  121. https://www.sciencedirect.com/science/article/abs/pii/S0161642006013145
  122. https://pubmed.ncbi.nlm.nih.gov/17198849/
  123. https://eandv.biomedcentral.com/articles/10.1186/s40662-015-0019-1
  124. https://www.healio.com/news/ophthalmology/20250402/innovations-in-phakic-iols-offer-improved-safety-customized-lenses
  125. https://crstoday.com/articles/mar-2025/improving-success-with-phakic-iols
  126. https://www.escrs.org/channels/eurotimes-articles/presbyopic-phakic-iols
  127. https://journals.lww.com/jcrs/fulltext/2025/11000/six_month_performance_and_safety_of_an.5.aspx
  128. https://www.nature.com/articles/s41598-024-81477-w
  129. https://www.ophthalmologytimes.com/view/eyebright-medical-receives-class-iii-certificate-from-national-medical-products-administration-in-china-for-its-phakic-intraocular-lens
  130. https://english.nmpa.gov.cn/2025-06/11/c_1101555.htm
  131. https://crstodayeurope.com/articles/nov-dec-24/ai-and-the-evolution-of-phakic-iols/
  132. https://www.researchgate.net/publication/368982542_A_clinical_trial_on_phakic_intraocular_lens_for_the_treatment_of_refractive_amblyopia_in_children_and_adolescents
Add your contribution
Related Hubs
User Avatar
No comments yet.